Healthy volunteers test new Alzheimer's drug in early safety study
NCT ID NCT07346495
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study is testing a single dose of remternetug in 24 healthy Chinese adults to see if it is safe and how the body processes it. Participants will have blood tests and be monitored for side effects over about 25 weeks. The study does not aim to treat any disease, but to gather important safety information for future research.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Shanghai Xuhui Central Hospital
Xuhui District, 20031, China
-
Xuanwu Hospital Capital Medical University
Beijing, 100053, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a new oral drug change future treatments? early safety trial begins
- Can brain scans unlock the secret to hearing in crowded rooms?
- Can a Light-Guided device make arterial sticks easier?
- Water workouts could be the key to back pain relief
- Could everyday disinfectants be harming us? a new study investigates
- Can a new drug keep the Heart's beat steady? trial puts verducatib to the test